Key clinical point: Patients with high-risk soft-tissue sarcomas benefit from adjuvant chemotherapy.
Major finding: Hazard ratios for death and disease progression in patients with a low probability of 10-year overall survival were 0.46 for each.
Study details: Retrospective analysis of a randomized phase 3 trial comparing adjuvant chemotherapy with observation in 290 patients with soft tissue sarcomas of the trunk wall or extremities.
Disclosures: The study was supported by the European Organisation for Research and Treatment of Cancer. Dr. Pasquali reported having no conflicts of interest.
Source: Pasquali S et al. ASCO 2018, Abstract 115118.
Pasquali S et al. ASCO 2018, Abstract 115118.